Patricia Carr - 27 Feb 2025 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role: SVP, Chief Accounting Officer
Signature: By: /s/Adam Guttmann, as attorney in fact For: Patricia Carr
Issuer symbol: JAZZ
Transactions as of: 27 Feb 2025
Net transactions value: -$381,909
Form type: 4
Filing time: 03 Mar 2025, 19:21:53 UTC
Previous filing: 22 Jan 2025
Next filing: 11 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JAZZ	Ordinary Shares	Options Exercise	$508,950	+4,500	+55%	$113.10	12,737	27 Feb 2025	Direct
transaction	JAZZ	Ordinary Shares	Sale	$649,873	-4,500	-35%	$144.42	8,237	27 Feb 2025	Direct
transaction	JAZZ	Ordinary Shares	Options Exercise	$38,612	+313	+3.8%	$123.36	8,550	27 Feb 2025	Direct
transaction	JAZZ	Ordinary Shares	Sale	$45,202	-313	-3.7%	$144.42	8,237	27 Feb 2025	Direct
transaction	JAZZ	Ordinary Shares	Disposed to Issuer	$52,840	-371	-4.5%	$142.43	7,866	27 Feb 2025	Direct	F1
transaction	JAZZ	Ordinary Shares	Disposed to Issuer	$70,788	-497	-6.3%	$142.43	7,369	27 Feb 2025	Direct	F1
transaction	JAZZ	Ordinary Shares	Award	$0	+2,889	+39%	$0.000000	10,258	27 Feb 2025	Direct	F2
transaction	JAZZ	Ordinary Shares	Sale	$110,767	-773	-7.5%	$143.30	9,485	28 Feb 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JAZZ	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-4,500	-100%	$0.000000	0	27 Feb 2025	Ordinary Shares	4,500	$113.10	Direct	F3
transaction	JAZZ	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-313	-100%	$0.000000	0	27 Feb 2025	Ordinary Shares	313	$123.36	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2	These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2025, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
F3	These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The options were fully vested as of the date of exercise.
F4	These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 25, 2016, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The options were fully vested as of the date of exercise.